Reuters: Global Markets: FDA approves Vivus drug for erectile dysfunction

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA approves Vivus drug for erectile dysfunction Apr 27th 2012, 18:16 WASHINGTON | Fri Apr 27, 2012 2:16pm EDT WASHINGTON (Reuters) - U.S. health regulators on Friday approved Vivus Inc.'s avanafil treatment for erectile dysfunction, giving the small company, which has struggled to bring a weight loss drug to market, a potentially lucrative commercial product. The U.S. Food and Drug Administration said the pill, which will compete with Pfizer's Inc's Viagra and other ED drugs, will be sold under the brand name Stendra. Vivus shares were up 4.5 percent to $25.53 on Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions